array(40) {
  [0]=>
  string(4) "6075"
  ["article_id"]=>
  string(4) "6075"
  [1]=>
  string(108) "X4 Pharmaceuticals receives breakthrough therapy designation from FDA for Mavorixafor to treat WHIM Syndrome"
  ["article_title"]=>
  string(108) "X4 Pharmaceuticals receives breakthrough therapy designation from FDA for Mavorixafor to treat WHIM Syndrome"
  [2]=>
  string(150) "Mavorixafor is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4, and is currently being investigate"
  ["short_description"]=>
  string(150) "Mavorixafor is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4, and is currently being investigate"
  [3]=>
  string(691) "
Mavorixafor is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4, and is currently being investigated in a pivotal Phase 3 global clinical trial, 4WHIM, 
&#nl
The post X4 Pharmaceuticals receives breakthrough therapy designation from FDA for Mavorixafor to treat WHIM Syndrome appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(691) "
Mavorixafor is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4, and is currently being investigated in a pivotal Phase 3 global clinical trial, 4WHIM, 
&#nl
The post X4 Pharmaceuticals receives breakthrough therapy designation from FDA for Mavorixafor to treat WHIM Syndrome appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(161) "https://www.pharmaceutical-business-review.com/news/x4-pharmaceuticals-receives-breakthrough-therapy-designation-from-fda-for-mavorixafor-to-treat-whim-syndrome/"
  ["blog_url"]=>
  string(161) "https://www.pharmaceutical-business-review.com/news/x4-pharmaceuticals-receives-breakthrough-therapy-designation-from-fda-for-mavorixafor-to-treat-whim-syndrome/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:49:10"
  ["create_at"]=>
  string(19) "2019-11-15 05:49:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6076"
  ["article_id"]=>
  string(4) "6076"
  [1]=>
  string(80) "Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure"
  ["article_title"]=>
  string(80) "Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure"
  [2]=>
  string(150) "The Empulse, which is the sixth phase III study in the Jardiance heart failure programme, will evaluate whether in-hospital administration of Jardianc"
  ["short_description"]=>
  string(150) "The Empulse, which is the sixth phase III study in the Jardiance heart failure programme, will evaluate whether in-hospital administration of Jardianc"
  [3]=>
  string(577) "
The Empulse, which is the sixth phase III study in the Jardiance heart failure programme, will evaluate whether in-hospital administration of Jardiance 10mg daily enhances heart failure outcomes 
&#nl
The post Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(577) "
The Empulse, which is the sixth phase III study in the Jardiance heart failure programme, will evaluate whether in-hospital administration of Jardiance 10mg daily enhances heart failure outcomes 
&#nl
The post Boehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/boehringer-eli-lilly-jardiance/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/boehringer-eli-lilly-jardiance/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:49:10"
  ["create_at"]=>
  string(19) "2019-11-15 05:49:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6077"
  ["article_id"]=>
  string(4) "6077"
  [1]=>
  string(68) "Roche’s risdiplam meets primary endpoint in phase 3 SMA trial"
  ["article_title"]=>
  string(68) "Roche’s risdiplam meets primary endpoint in phase 3 SMA trial"
  [2]=>
  string(150) "Risdiplam has been designed to be a survival motor neuron-2 (SMN2) splicing modifier. The drug works by durably increasing and maintaining SMN protein"
  ["short_description"]=>
  string(150) "Risdiplam has been designed to be a survival motor neuron-2 (SMN2) splicing modifier. The drug works by durably increasing and maintaining SMN protein"
  [3]=>
  string(559) "
Risdiplam has been designed to be a survival motor neuron-2 (SMN2) splicing modifier. The drug works by durably increasing and maintaining SMN protein levels throughout the central nervous 
&#nl
The post Roche’s risdiplam meets primary endpoint in phase 3 SMA trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(559) "
Risdiplam has been designed to be a survival motor neuron-2 (SMN2) splicing modifier. The drug works by durably increasing and maintaining SMN protein levels throughout the central nervous 
&#nl
The post Roche’s risdiplam meets primary endpoint in phase 3 SMA trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/roches-risdiplam-sunfish-trial/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/roches-risdiplam-sunfish-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:49:10"
  ["create_at"]=>
  string(19) "2019-11-15 05:49:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6078"
  ["article_id"]=>
  string(4) "6078"
  [1]=>
  string(88) "NEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines"
  ["article_title"]=>
  string(88) "NEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines"
  [2]=>
  string(150) "NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral "
  ["short_description"]=>
  string(150) "NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral "
  [3]=>
  string(643) "
NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that 
&#nl
The post NEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(643) "
NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that 
&#nl
The post NEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(141) "https://www.pharmaceutical-business-review.com/news/nec-and-vaximm-announce-collaboration-to-advance-personalized-neoantigen-cancer-vaccines/"
  ["blog_url"]=>
  string(141) "https://www.pharmaceutical-business-review.com/news/nec-and-vaximm-announce-collaboration-to-advance-personalized-neoantigen-cancer-vaccines/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:49:10"
  ["create_at"]=>
  string(19) "2019-11-15 05:49:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6141"
  ["article_id"]=>
  string(4) "6141"
  [1]=>
  string(71) "New Bespoke service for small and emerging Pharma and Biotech companies"
  ["article_title"]=>
  string(71) "New Bespoke service for small and emerging Pharma and Biotech companies"
  [2]=>
  string(150) "A new, tailor-made service for small and emerging Pharma and Biotech companies has just been launched by specialist scientific consulting organization"
  ["short_description"]=>
  string(150) "A new, tailor-made service for small and emerging Pharma and Biotech companies has just been launched by specialist scientific consulting organization"
  [3]=>
  string(551) "A new, tailor-made service for small and emerging Pharma and Biotech companies has just been launched by specialist scientific consulting organization, G&L Scientific. Under the name Bespoke, this niche service will provide fully-integrated Regulatory and Quality support shepherding products through development and on to market.Based and founded on many years of extensive practical experience with more than 2,500 consultants in over 100 countries, the team at G&L has a thorough understanding of the unique needs...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(551) "A new, tailor-made service for small and emerging Pharma and Biotech companies has just been launched by specialist scientific consulting organization, G&L Scientific. Under the name Bespoke, this niche service will provide fully-integrated Regulatory and Quality support shepherding products through development and on to market.Based and founded on many years of extensive practical experience with more than 2,500 consultants in over 100 countries, the team at G&L has a thorough understanding of the unique needs...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(104) "http://www.realwire.com/releases/New-Bespoke-service-for-small-and-emerging-Pharma-and-Biotech-companies"
  ["blog_url"]=>
  string(104) "http://www.realwire.com/releases/New-Bespoke-service-for-small-and-emerging-Pharma-and-Biotech-companies"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:50:20"
  ["create_at"]=>
  string(19) "2019-11-15 05:50:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6221"
  ["article_id"]=>
  string(4) "6221"
  [1]=>
  string(52) "US FDA accepts regulatory submission for Selumetinib"
  ["article_title"]=>
  string(52) "US FDA accepts regulatory submission for Selumetinib"
  [2]=>
  string(150) "This is the first acceptance of a regulatory submission for an oral MEK 1/2 monotherapy for patients with NF1, a rare and incurable genetic condition."
  ["short_description"]=>
  string(150) "This is the first acceptance of a regulatory submission for an oral MEK 1/2 monotherapy for patients with NF1, a rare and incurable genetic condition."
  [3]=>
  string(547) "
This is the first acceptance of a regulatory submission for an oral MEK 1/2 monotherapy for patients with NF1, a rare and incurable genetic condition. A Prescription Drug 
&#nl
The post US FDA accepts regulatory submission for Selumetinib appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(547) "
This is the first acceptance of a regulatory submission for an oral MEK 1/2 monotherapy for patients with NF1, a rare and incurable genetic condition. A Prescription Drug 
&#nl
The post US FDA accepts regulatory submission for Selumetinib appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(105) "https://www.pharmaceutical-business-review.com/news/us-fda-accepts-regulatory-submission-for-selumetinib/"
  ["blog_url"]=>
  string(105) "https://www.pharmaceutical-business-review.com/news/us-fda-accepts-regulatory-submission-for-selumetinib/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-16 11:14:58"
  ["create_at"]=>
  string(19) "2019-11-16 11:14:58"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6222"
  ["article_id"]=>
  string(4) "6222"
  [1]=>
  string(124) "EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform"
  ["article_title"]=>
  string(124) "EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform"
  [2]=>
  string(155) "The purpose of this funding round, which will be split into three tranches, is to progress the late-stage clinical development of EpicentRx’s lead a"
  ["short_description"]=>
  string(155) "The purpose of this funding round, which will be split into three tranches, is to progress the late-stage clinical development of EpicentRx’s lead a"
  [3]=>
  string(716) "
The purpose of this funding round, which will be split into three tranches, is to progress the late-stage clinical development of EpicentRx’s lead anticancer agent, RRx-001, and proprietary 
&#nl
The post EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(716) "
The purpose of this funding round, which will be split into three tranches, is to progress the late-stage clinical development of EpicentRx’s lead anticancer agent, RRx-001, and proprietary 
&#nl
The post EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(176) "https://www.pharmaceutical-business-review.com/news/epicentrx-closes-35m-series-d-financing-to-support-development-of-small-molecule-immunotherapy-and-oncolytic-viral-platform/"
  ["blog_url"]=>
  string(176) "https://www.pharmaceutical-business-review.com/news/epicentrx-closes-35m-series-d-financing-to-support-development-of-small-molecule-immunotherapy-and-oncolytic-viral-platform/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-16 11:14:58"
  ["create_at"]=>
  string(19) "2019-11-16 11:14:58"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6223"
  ["article_id"]=>
  string(4) "6223"
  [1]=>
  string(48) "Shionogi gets FDA approval for cUTI drug Fetroja"
  ["article_title"]=>
  string(48) "Shionogi gets FDA approval for cUTI drug Fetroja"
  [2]=>
  string(150) "Fetroja has been approved for patients 18 years of age or older who have limited or no alternative treatment options to treat cUTI, including pyelonep"
  ["short_description"]=>
  string(150) "Fetroja has been approved for patients 18 years of age or older who have limited or no alternative treatment options to treat cUTI, including pyelonep"
  [3]=>
  string(514) "
Fetroja has been approved for patients 18 years of age or older who have limited or no alternative treatment options to treat cUTI, including pyelonephritis. It can be 
&#nl
The post Shionogi gets FDA approval for cUTI drug Fetroja appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(514) "
Fetroja has been approved for patients 18 years of age or older who have limited or no alternative treatment options to treat cUTI, including pyelonephritis. It can be 
&#nl
The post Shionogi gets FDA approval for cUTI drug Fetroja appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/shionogi-cuti-drug-fetroja/"
  ["blog_url"]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/shionogi-cuti-drug-fetroja/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-16 11:14:58"
  ["create_at"]=>
  string(19) "2019-11-16 11:14:58"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6322"
  ["article_id"]=>
  string(4) "6322"
  [1]=>
  string(50) "Alkermes to buy Rodin Therapeutics for up to $950m"
  ["article_title"]=>
  string(50) "Alkermes to buy Rodin Therapeutics for up to $950m"
  [2]=>
  string(150) "As per the terms of the deal, Rodin’s security holders will secure an upfront cash payment of $100m upon completion of the deal. Rodin is also e"
  ["short_description"]=>
  string(150) "As per the terms of the deal, Rodin’s security holders will secure an upfront cash payment of $100m upon completion of the deal. Rodin is also e"
  [3]=>
  string(510) "
As per the terms of the deal, Rodin’s security holders will secure an upfront cash payment of $100m upon completion of the deal. Rodin is also eligible to 
&#nl
The post Alkermes to buy Rodin Therapeutics for up to $950m appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(510) "
As per the terms of the deal, Rodin’s security holders will secure an upfront cash payment of $100m upon completion of the deal. Rodin is also eligible to 
&#nl
The post Alkermes to buy Rodin Therapeutics for up to $950m appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/alkermes-rodin-therapeutics/"
  ["blog_url"]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/alkermes-rodin-therapeutics/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-19 16:35:09"
  ["create_at"]=>
  string(19) "2019-11-19 16:35:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6323"
  ["article_id"]=>
  string(4) "6323"
  [1]=>
  string(78) "Novartis’ Adakveo approved by FDA to reduce VOCs in sickle cell disease"
  ["article_title"]=>
  string(78) "Novartis’ Adakveo approved by FDA to reduce VOCs in sickle cell disease"
  [2]=>
  string(150) "Formerly known as SEG101, Adakveo has been approved for reducing the incidents of vaso-occlusive crises (VOCs), or pain crises, in adult patients with"
  ["short_description"]=>
  string(150) "Formerly known as SEG101, Adakveo has been approved for reducing the incidents of vaso-occlusive crises (VOCs), or pain crises, in adult patients with"
  [3]=>
  string(562) "
Formerly known as SEG101, Adakveo has been approved for reducing the incidents of vaso-occlusive crises (VOCs), or pain crises, in adult patients with sickle cell disease, aged 16 
&#nl
The post Novartis’ Adakveo approved by FDA to reduce VOCs in sickle cell disease appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(562) "
Formerly known as SEG101, Adakveo has been approved for reducing the incidents of vaso-occlusive crises (VOCs), or pain crises, in adult patients with sickle cell disease, aged 16 
&#nl
The post Novartis’ Adakveo approved by FDA to reduce VOCs in sickle cell disease appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/novartis-adakveo-fda-sickle-cell/"
  ["blog_url"]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/novartis-adakveo-fda-sickle-cell/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-19 16:35:09"
  ["create_at"]=>
  string(19) "2019-11-19 16:35:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6324"
  ["article_id"]=>
  string(4) "6324"
  [1]=>
  string(113) "The Medicines Company announces that the ORION-10 study of inclisiran showed durable and potent lowering of LDL-C"
  ["article_title"]=>
  string(113) "The Medicines Company announces that the ORION-10 study of inclisiran showed durable and potent lowering of LDL-C"
  [2]=>
  string(150) "In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstr"
  ["short_description"]=>
  string(150) "In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstr"
  [3]=>
  string(701) "
In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile. Full study results 
&#nl
The post The Medicines Company announces that the ORION-10 study of inclisiran showed durable and potent lowering of LDL-C appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(701) "
In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile. Full study results 
&#nl
The post The Medicines Company announces that the ORION-10 study of inclisiran showed durable and potent lowering of LDL-C appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(166) "https://www.pharmaceutical-business-review.com/news/the-medicines-company-announces-that-the-orion-10-study-of-inclisiran-showed-durable-and-potent-lowering-of-ldl-c/"
  ["blog_url"]=>
  string(166) "https://www.pharmaceutical-business-review.com/news/the-medicines-company-announces-that-the-orion-10-study-of-inclisiran-showed-durable-and-potent-lowering-of-ldl-c/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-19 16:35:09"
  ["create_at"]=>
  string(19) "2019-11-19 16:35:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "6325"
  ["article_id"]=>
  string(4) "6325"
  [1]=>
  string(48) "Qtrilmet approved in EU to treat type-2 diabetes"
  ["article_title"]=>
  string(48) "Qtrilmet approved in EU to treat type-2 diabetes"
  [2]=>
  string(150) "The approval is based on data from five Phase III trials which evaluated combinations of Forxiga (dapagliflozin) and Onglyza (saxagliptin) on a backgr"
  ["short_description"]=>
  string(150) "The approval is based on data from five Phase III trials which evaluated combinations of Forxiga (dapagliflozin) and Onglyza (saxagliptin) on a backgr"
  [3]=>
  string(553) "
The approval is based on data from five Phase III trials which evaluated combinations of Forxiga (dapagliflozin) and Onglyza (saxagliptin) on a background of metformin in patients with 
&#nl
The post Qtrilmet approved in EU to treat type-2 diabetes appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(553) "
The approval is based on data from five Phase III trials which evaluated combinations of Forxiga (dapagliflozin) and Onglyza (saxagliptin) on a background of metformin in patients with 
&#nl
The post Qtrilmet approved in EU to treat type-2 diabetes appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(101) "https://www.pharmaceutical-business-review.com/news/qtrilmet-approved-in-eu-to-treat-type-2-diabetes/"
  ["blog_url"]=>
  string(101) "https://www.pharmaceutical-business-review.com/news/qtrilmet-approved-in-eu-to-treat-type-2-diabetes/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-19 16:35:09"
  ["create_at"]=>
  string(19) "2019-11-19 16:35:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}